Limits...
In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus

Testosterone and estradiol plasma levels determined at the end of the experimental sessions in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups. BCP administration for two weeks significantly increased E and T plasma levels, whereas BCP+DHA completely reversed this increase. Histograms represent means ± SEM. Estradiol: *P < 0.04 versus OIL and #P < 0.03 versus BCP+DHA. Testosterone: *P < 0.03 versus OIL and #P < 0.04 versus BCP+DHA.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4109702&req=5

fig9: Testosterone and estradiol plasma levels determined at the end of the experimental sessions in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups. BCP administration for two weeks significantly increased E and T plasma levels, whereas BCP+DHA completely reversed this increase. Histograms represent means ± SEM. Estradiol: *P < 0.04 versus OIL and #P < 0.03 versus BCP+DHA. Testosterone: *P < 0.03 versus OIL and #P < 0.04 versus BCP+DHA.

Mentions: Estradiol (E) and Testosterone (T) Plasma Levels. The effect of treatments on E and T plasma levels was examined at the end of the experiment. One-way ANOVA showed a significant effect of treatment on the E and T levels (F2,14 = 3.78, P = 0.048 and F2,14 = 3.76, P = 0.049, resp.). As shown in Figure 9, BCP treatment significantly increased E and T plasma levels (P < 0.04 and P < 0.026, resp.), while there were no changes in these hormones in the BCP+DHA group. In particular, T levels were 90% higher and E more than 150% higher in the BCP group than in the OIL and BCP+DHA groups.


In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Testosterone and estradiol plasma levels determined at the end of the experimental sessions in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups. BCP administration for two weeks significantly increased E and T plasma levels, whereas BCP+DHA completely reversed this increase. Histograms represent means ± SEM. Estradiol: *P < 0.04 versus OIL and #P < 0.03 versus BCP+DHA. Testosterone: *P < 0.03 versus OIL and #P < 0.04 versus BCP+DHA.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4109702&req=5

fig9: Testosterone and estradiol plasma levels determined at the end of the experimental sessions in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups. BCP administration for two weeks significantly increased E and T plasma levels, whereas BCP+DHA completely reversed this increase. Histograms represent means ± SEM. Estradiol: *P < 0.04 versus OIL and #P < 0.03 versus BCP+DHA. Testosterone: *P < 0.03 versus OIL and #P < 0.04 versus BCP+DHA.
Mentions: Estradiol (E) and Testosterone (T) Plasma Levels. The effect of treatments on E and T plasma levels was examined at the end of the experiment. One-way ANOVA showed a significant effect of treatment on the E and T levels (F2,14 = 3.78, P = 0.048 and F2,14 = 3.76, P = 0.049, resp.). As shown in Figure 9, BCP treatment significantly increased E and T plasma levels (P < 0.04 and P < 0.026, resp.), while there were no changes in these hormones in the BCP+DHA group. In particular, T levels were 90% higher and E more than 150% higher in the BCP group than in the OIL and BCP+DHA groups.

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus